These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 17696578)

  • 21. A multicenter study comparing intravenous meropenem with clindamycin plus gentamicin for the treatment of acute gynecologic and obstetric pelvic infections in hospitalized women.
    Hemsell DL; Martens MG; Faro S; Gall S; McGregor JA
    Clin Infect Dis; 1997 Feb; 24 Suppl 2():S222-30. PubMed ID: 9126697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and effectiveness of meropenem in infants with suspected or complicated intra-abdominal infections.
    Cohen-Wolkowiez M; Poindexter B; Bidegain M; Weitkamp JH; Schelonka RL; Randolph DA; Ward RM; Wade K; Valencia G; Burchfield D; Arrieta A; Mehta V; Walsh M; Kantak A; Rasmussen M; Sullivan JE; Finer N; Rich W; Brozanski BS; van den Anker J; Blumer J; Laughon M; Watt KM; Kearns GL; Capparelli EV; Martz K; Berezny K; Benjamin DK; Smith PB;
    Clin Infect Dis; 2012 Dec; 55(11):1495-502. PubMed ID: 22955430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Carbapenems and monobactams: imipenem, meropenem, and aztreonam.
    Hellinger WC; Brewer NS
    Mayo Clin Proc; 1999 Apr; 74(4):420-34. PubMed ID: 10221472
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imipenem/cilastatin therapy for serious infections in neonates and infants.
    Nalin DR; Jacobsen CA
    Scand J Infect Dis Suppl; 1987; 52():46-55. PubMed ID: 3331042
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients.
    Kuo BI; Fung CP; Liu CY
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):361-7. PubMed ID: 10862445
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meropenem--a new parenteral broad-spectrum antibiotic.
    Med Lett Drugs Ther; 1996 Sep; 38(984):88-90. PubMed ID: 8828521
    [No Abstract]   [Full Text] [Related]  

  • 27. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group.
    Klugman KP; Dagan R
    Antimicrob Agents Chemother; 1995 May; 39(5):1140-6. PubMed ID: 7625802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of imipenem/cilastatin in neurocritical care patients.
    Hoffman J; Trimble J; Brophy GM
    Neurocrit Care; 2009; 10(3):403-7. PubMed ID: 19116700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Meropenem. A pharmacoeconomic review of its use in serious infections.
    Holliday SM; Benfield P
    Pharmacoeconomics; 1998 Mar; 13(3):359-77. PubMed ID: 10178661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial.
    Basoli A; Meli EZ; Mazzocchi P; Speranza V
    Scand J Infect Dis; 1997; 29(5):503-8. PubMed ID: 9435041
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Empirical monotherapy with meropenem in serious bacterial infections in children.
    Hsu HL; Lu CY; Tseng HY; Lee PI; Lai HP; Lin WC; Hsieh YC; Lee CY; Huang LM
    J Microbiol Immunol Infect; 2001 Dec; 34(4):275-80. PubMed ID: 11825008
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imipenem/cilastatin therapy of serious infections: a U.S. multicenter noncomparative trial.
    Calandra GB; Hesney M; Brown KR
    Clin Ther; 1985; 7(2):225-38. PubMed ID: 3886144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants.
    Hornik CP; Herring AH; Benjamin DK; Capparelli EV; Kearns GL; van den Anker J; Cohen-Wolkowiez M; Clark RH; Smith PB;
    Pediatr Infect Dis J; 2013 Jul; 32(7):748-53. PubMed ID: 23838776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meropenem in elderly and renally impaired patients.
    Cunha BA
    Int J Antimicrob Agents; 1999 Feb; 11(2):167-77. PubMed ID: 10221422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Meropenem in elderly and renally impaired patients.
    Cunha BA
    Int J Antimicrob Agents; 1998 May; 10(2):107-17. PubMed ID: 9716287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selecting therapy for serious infections in children: maximizing safety and efficacy.
    Bradley JS
    Diagn Microbiol Infect Dis; 1998 Jun; 31(2):405-10. PubMed ID: 9635916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the activity of meropenem with that of other agents in the treatment of intraabdominal, obstetric/gynecologic, and skin and soft tissue.
    Pitkin D; Sheikh W; Wilson S; Hemsell D; Nichols R; Nadler H; Dowzicky M
    Clin Infect Dis; 1995 Jun; 20 Suppl 2():S372-5. PubMed ID: 7548602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Retrospective Study on the Incidence of Seizures among Neurosurgical Patients Who Treated with Imipenem/Cilastatin or Meropenem.
    Wu Y; Chen K; Shi Z; Wang Q
    Curr Pharm Biotechnol; 2014; 15(8):685-90. PubMed ID: 25051950
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Carbapenems in paediatrics.
    Blumer JL
    Scand J Infect Dis Suppl; 1995; 96():38-44. PubMed ID: 7652502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia.
    Bartoloni A; Strohmeyer M; Corti G; Buonomini MI; Franchino L; Romanelli G; Moretti AM; De Vizzi GB; Petraglia A; Mancini P; Atzeni R; Fogliani V; Giura R; Paradisi F
    Drugs Exp Clin Res; 1999; 25(6):243-52. PubMed ID: 10713862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.